Rubicon Company Profile
✉ Email this page to a colleague
What is the competitive landscape for RUBICON, and what generic and branded alternatives to RUBICON drugs are available?
RUBICON has sixty-three approved drugs.
Summary for Rubicon
| US Patents: | 0 |
| Tradenames: | 52 |
| Ingredients: | 52 |
| NDAs: | 63 |
Drugs and US Patents for Rubicon
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rubicon | POTASSIUM CHLORIDE | potassium chloride | FOR SOLUTION;ORAL | 214108-001 | Mar 24, 2022 | AA | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Rubicon | GLIPIZIDE | glipizide | TABLET;ORAL | 214874-001 | Oct 3, 2023 | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Rubicon | DIHYDROERGOTAMINE MESYLATE | dihydroergotamine mesylate | SPRAY, METERED;NASAL | 216881-001 | Jun 22, 2023 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Rubicon | LORATADINE | loratadine | TABLET, ORALLY DISINTEGRATING;ORAL | 214280-001 | Sep 10, 2020 | OTC | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Rubicon | ACETAZOLAMIDE | acetazolamide | TABLET;ORAL | 215101-002 | Aug 19, 2021 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Rubicon | LAMOTRIGINE | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 202887-001 | Jun 17, 2013 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Rubicon | AMITRIPTYLINE HYDROCHLORIDE | amitriptyline hydrochloride | TABLET;ORAL | 215376-004 | May 1, 2023 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
